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Abstract
Objective: We investigated whether severe, MRI-visible perivascular spaces
(PVS) in the cerebral hemisphere white matter (centrum semiovale) are more
common in patients with pathologyproven cerebral amyloid angiopathy (CAA)
than in those with pathology-proven non-CAA-related intracerebral hemorrhage
(ICH). Methods: Using a validated 4-point scale on axial T2-weighted MRI, we
compared PVS in patients with pathology-proven CAA to PVS in those with
spontaneous ICH but no histopathologic evidence of CAA. In a preliminary
analysis restricted to patients with T2*-weighted gradient-recalled echo MRI, we
also investigated whether including severe centrum semiovale PVS increases
the sensitivity of existing diagnostic criteria for probable CAA. Results: Fourteen
patients with CAA and 10 patients with non-CAA-related ICH were included. Eight
of the patients with CAA were admitted for symptomatic, spontaneous lobar ICH,
1 because of ischemic stroke, 1 with transient focal neurologic episodes, an...
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White matter perivascular spaces
AnMRI marker in pathology-proven cerebral amyloid angiopathy?
ABSTRACT
Objective: We investigated whether severe, MRI-visible perivascular spaces (PVS) in the cerebral
hemisphere white matter (centrum semiovale) are more common in patients with pathology-
proven cerebral amyloid angiopathy (CAA) than in those with pathology-proven non–CAA-related
intracerebral hemorrhage (ICH).
Methods: Using a validated 4-point scale on axial T2-weighted MRI, we compared PVS in patients
with pathology-proven CAA to PVS in those with spontaneous ICH but no histopathologic evi-
dence of CAA. In a preliminary analysis restricted to patients with T2*-weighted gradient-recalled
echo MRI, we also investigated whether including severe centrum semiovale PVS increases the
sensitivity of existing diagnostic criteria for probable CAA.
Results: Fourteen patients with CAA and 10 patients with non–CAA-related ICH were included.
Eight of the patients with CAAwere admitted for symptomatic, spontaneous lobar ICH, 1 because
of ischemic stroke, 1 with transient focal neurologic episodes, and 4 due to cognitive decline.
Severe (.20) centrum semiovale PVS were more frequent in patients with CAA compared to
controls (12/14 [85.7%; 95%confidence interval (CI): 57.2%–98.2%] vs 0/10 [1-sided 95%CI:
0%–30.8%], p , 0.0005); this was robust to adjustment for age. The original Boston criteria for
probable CAA showed a sensitivity of 76.9% (95%CI: 46.2%–95%), which increased to 92.3%
(95% CI: 64%–99.8%), without loss of specificity, after including severe centrum semiovale PVS.
Conclusions: Severe centrum semiovale PVS on MRI may be a promising new neuroimaging marker
for the in vivo diagnosis of CAA. However, our findings are preliminary and require confirmation and
external validation in larger cohorts of pathology-proven CAA. Neurology® 2014;82:57–62
GLOSSARY
AD5 Alzheimer disease; CAA5 cerebral amyloid angiopathy; CI5 confidence interval;GRE5 gradient-recalled echo; ICH5
intracerebral hemorrhage; PVS 5 perivascular spaces.
Sporadic cerebral amyloid angiopathy (CAA),1 caused by progressive vascular amyloid-b depo-
sition in small cortical and leptomeningeal vessels, is a major and increasingly frequent cause of
lobar intracerebral hemorrhage (ICH) and cognitive impairment in older patients.2–4 CAA is
associated with neuroimaging markers, including lobar ICH and strictly lobar cerebral micro-
bleeds, which allow its clinical-radiologic diagnosis using the Boston criteria.2,5,6 However, these
criteria have limited sensitivity in some studies; new noninvasive diagnostic markers of CAA are
therefore needed, particularly to identify early disease.2,3
Recently, perivascular spaces (PVS) have emerged as a potential MRI marker of the presence
and severity of cerebral small-vessel disease.7–12 PVS are interstitial fluid-filled cavities surround-
ing small penetrating vessels, which function to allow interstitial fluid and solute efflux from the
brain.13–15 CAA almost invariably accompanies Alzheimer disease (AD), and in this setting
vascular amyloid-b is associated with enlargement of PVS.16–19 However, whether PVS are
associated with sporadic CAA is not known. We hypothesized that progressive amyloid-b
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deposition in CAA impairs interstitial fluid
drainage, causing severe, MRI-visible PVS in
the cerebral hemisphere white matter (cen-
trum semiovale). To test this hypothesis, we
compared the prevalence of severe centrum
semiovale PVS in patients with pathology-
proven sporadic CAA to the prevalence in
patients with pathology-proven non–CAA-
related spontaneous ICH. In a preliminary
analysis, we also investigated whether includ-
ing severe centrum semiovale PVS increases
the sensitivity of existing diagnostic criteria
for CAA.5
METHODS Study participants and data collection. We
included all eligible patients from 4 stroke centers identified retro-
spectively by a systematic keyword search of pathology reports.
Cases were defined as subjects with both pathology-proven CAA
(from routinely collected brain biopsy, biopsy at hematoma evacu-
ation, or autopsy) and adequate T2-weightedMRI sequences. Con-
trols were defined as subjects with spontaneous, symptomatic ICH,
no pathologic evidence of CAA, and adequate T2-weighted MRI.
Standard protocol approvals, registrations, and patient
consents. The study was approved by the National Hospital for
Neurology and Neurosurgery and Institute of Neurology Joint
Research Ethics Committee and the Commission d’Ethique Bio-
medicale Hospitalo Facultaire of the Faculte de Medicine (Uni-
versite Catholique de Louvain).
Pathologic analysis. Brain biopsies or hematoma evacuation
samples were fixed in 10% formalin, embedded in paraffin, and
processed for paraffin sectioning. Routine hematoxylin & eosin
staining was performed for morphologic assessment, and the pres-
ence or absence of vascular amyloid-b deposition was confirmed
by immunohistochemical detection. Samples not containing any
assessable vessels were excluded from analysis. We assessed CAA
presence and severity in all available vessels (in all cases from solid
tissue fragments except in one case from isolated vessels); we also
determined, wherever possible, whether vessels were leptomenin-
geal or parenchymal. CAA severity was graded using the modified
Vonsattel grading system20,21; all included CAA cases had a sever-
ity of at least grade 2 (i.e., replacement of the whole vessel wall by
amyloid-b), in line with previous recommendations.21 Non-CAA
cases were defined as absence of vascular amyloid-b deposition.
MRI data and analysis. Mandatory imaging included axial T2-
weighted sequences in all patients (slice thickness: 5 mm, field
strength: 1.5T) and, whenever available, T2*-weighted gradient-
recalled echo (T2*-GRE) sequences. MRIs were reviewed blinded
to clinical details, histopathologic diagnosis, and microbleeds status.
PVS were defined and rated on T2-weighted MRIs, according to
STandards for ReportIng Vascular changes on nEuroimaging
(STRIVE),12 by a trained observer using a validated 4-point visual
rating scale (0 5 no PVS, 1 5 # 10 PVS, 2 5 11–20 PVS, 3 5
21–40 PVS, and 45. 40 PVS) in the basal ganglia and centrum
semiovale (cerebral hemisphere white matter).9,22 Intrarater reliabil-
ity testing of the PVS scale using an independent dataset of ICH
scans (n5 30) showed an intrarater Cohen kappa of 0.91 for basal
ganglia PVS and 0.82 for centrum semiovale PVS.
Statistics. We prespecified a definition of severe centrum semio-
vale PVS as .20 (grade 3). Although arbitrary, this definition is
in line with the most severe category of white matter PVS used in a
previous study (and found to relate to vascular risk factors)23 and
provided 2 numerically balanced categories consistent with our aim
of increasing the sensitivity of CAA diagnosis. We compared both
the crude and age-standardized prevalence of severe PVS between
groups using the Fisher exact test. We calculated the sensitivity and
specificity after the addition of severe centrum semiovale PVS to the
original Boston diagnostic criteria for CAA (including strictly lobar
cerebral microbleeds),5 in line with Standards for Reporting of
Diagnostic Accuracy (STARD) guidelines.24 Significance level
was set at 0.05 for all analyses. Statistical analyses were carried
out using STATA (Version 11.2, StataCorp.).
RESULTS Fourteen CAA patients and 10 non-CAA
ICH patients were included (table 1) out of 56 screened;
30 patients were excluded because of no MRI available,
1 non-CAA patient because of no evidence of ICH on
MRI, and 1 non-CAA patient because the tissue sample
contained no assessable vessels. Eight of the CAA
patients were admitted with symptomatic, spontaneous
lobar ICH, 1 with ischemic stroke, 1 with transient focal
neurologic episodes, and 4 with cognitive decline (1 of
these also had radiologic evidence of a previous ICH).
All non-CAA patients were admitted with symptomatic,
spontaneous ICH. Twenty-three of the 24 available
pathologic samples contained at least 2 assessable paren-
chymal or leptomeningeal vessels. There were 23 solid
tissue samples including vessels and 1 sample including
only isolated vessels. All 14 CAA cases contained .10
assessable vessels: 12 cases with both cortical and lepto-
meningeal vessels and 2 with only leptomeningeal ves-
sels. Of the 10 non-CAA cases, 4 contained .10
assessable vessels while the other 6 contained a median
number of 2 assessable vessels (interquartile range 2–3);
1 case contained both cortical and leptomeningeal ves-
sels, 5 only cortical vessels, and 3 only leptomeningeal
vessels. In the case containing only isolated vessels, their
origin could not be determined. The amount of avail-
able pathologic tissue was generally greater in the CAA
cases than the non-CAA cases.
Severe (.20) centrum semiovale PVS were de-
tected in 85.7% (95% confidence interval [CI]:
57.2%–98.2%) of patients with histopathologically
confirmed CAA but in none (1-sided 95% CI: 0%–
30.8%) of the controls with histopathologically con-
firmed non-CAA ICH (p, 0.0005) (figure). The age-
standardized prevalences of severe centrum semiovale
PVS were 85.7% (95% CI: 65.7%–100%) in the
CAA group vs 0% in the non-CAA ICH group. The
prevalence of the most severe category of centrum
semiovale PVS (.40) was also higher in CAA
than non-CAA ICH (table 1). Within the CAA group,
7/8 (87.5%; 95% CI: 47.4%–99.7%) patients who
presented with symptomatic lobar ICH had severe cen-
trum semiovale PVS (p , 0.0005 compared with the
non-CAA ICH group). There was no difference in the
prevalence of any basal ganglia PVS category between
the CAA and non-CAA ICH groups.
58 Neurology 82 January 7, 2014
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
T2*-GREMRI was available in 13 CAA and 8 non-
CAA ICH patients. Adding severe centrum semiovale
PVS (.20 PVS) to the original Boston criteria for
CAA resulted in the diagnostic upgrading of 3 patients
(table 2). The original Boston criteria showed a sensi-
tivity of 92.3% (95% CI: 64%–99.8%) for possible or
probable CAA diagnosis, while inclusion of severe cen-
trum semiovale PVS increased their sensitivity to 100%
(95% CI: 75.3%–100%), without loss of specificity
(62.5%; 95% CI: 24.5%–91.5%). For probable
CAA, the original Boston criteria had a sensitivity of
76.9% (95%CI: 46.2%–95%); inclusion of severe cen-
trum semiovale PVS increased this to 92.3% (95% CI:
64%–99.8%). The specificity for probable CAA was
87.5% (95% CI 47.3%–99.7%) for both criteria.
DISCUSSION We have shown that severe PVS in the
centrum semiovale white matter are more common in
subjects with pathology-proven sporadic CAA than
control non-CAA subjects. These findings suggest
that in this patient population severe centrum semio-
vale PVS may be a promising new neuroimaging
marker to improve the sensitivity of in vivo diagnosis
of CAA. However, the sensitivity and specificity of
severe centrum semiovale PVS require external valida-
tion, ideally in a larger independent cohort.
PVS are a key route for the drainage of interstitial
fluid and solutes (including soluble amyloid-b) from
the brain. Progressive amyloid-b deposition in small
cortical and leptomeningeal arteries in CAA could
gradually impair perivascular drainage, causing retro-
grade dilation of PVS in the underlying white matter
of the centrum semiovale either by blocking bulk flow
or by diminishing the pulsatility of small vessels
(required for efficient interstitial fluid drainage) due
to smooth muscle cell loss.13,25 Impaired perivascular
Table 1 Patient and imaging characteristics
CAAa (N 5 14) Non-CAA ICHa (N 5 10) p Value
Age, median (IQR), y 66.9 (65.3–71.4) 56.9 (48.8–66.5) 0.035b
Sex, female 11 (78.6%) 5 (50%) 0.204
History of hypertension 4 (28.6%) 3 (30%) 1.000
Presence of radiologic ICH 9 (64.3%) 10 (100%) 0.053
Lobar ICH on MRI 9 (64.3%) 8 (80%) 0.653
Deep ICH on MRI 0 (0%) 2 (20%) 0.163
CMBs (T2*-GRE MRI was available in
13 CAA and 8 non-CAA patients)
CMBs presence 11/13 (84.6%) 5/8 (62.5%) 0.325
Lobar (cortical-subcortical) CMBs 11/13 (84.6%) 1/8 (12.5%) 0.002b
Deep CMBs 1/13 (7.7%) 2/8 (25%) 0.531
Cerebellar CMBs 0/13 (0%) 1/8 (12.5%) 0.381
PVS centrum semiovale
Severe PVS (>20) 12 (85.7%) 0 (0%) ,0.0005b
No PVS 0 (0%) 1 (10%) 0.417
1–10 PVS 0 (0%) 4 (40%) 0.020b
11–20 PVS 2 (14.3%) 5 (50%) 0.085
21–40 PVS 6 (42.9%) 0 (0%) 0.024b
>40 PVS 6 (42.9%) 0 (0%) 0.024b
PVS basal ganglia
1–10 PVS 13 (92.9%) 10 (90%) 1.000
11–20 PVS 1 (7.1%) 1 (10%) 1.000
21–40 PVS 0 0 —
>40 PVS 0 0 —
Abbreviations: CAA 5 cerebral amyloid angiography; CMB 5 cerebral microbleed; GRE 5 gradient-recalled echo; ICH 5
intracerebral hemorrhage; IQR 5 interquartile range; PVS 5 perivascular spaces.
Data are n (%), unless otherwise noted. We compared clinical characteristics between the 2 groups of patients using the
Fisher exact test for categorical variables and the Mann-Whitney U test for age (not normally distributed continuous
variable).
aCAA cases: 8 hematoma evacuations, 5 brain biopsies, and 1 autopsy; non-CAA ICH: 10 hematoma evacuations; CAA
severity grading: Vonsattel grade 2 (n 5 6), grade 3 (n 5 6), and grade 4 (n 5 2).21
bStatistically significant difference at p , 0.05.
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drainage could then further exacerbate vascular and
perivascular amyloid-b deposition, creating a “feed-
forward loop.”10,15 Consistent with this hypothesis, a
postmortem study of AD found that amyloid-b
blocks perivascular drainage pathways in CAA associ-
ated with AD, and the degree of enlargement of white
matter PVS correlates with CAA severity.16 Moreover,
a recent MRI study in ICH patients reported that
very severe centrum semiovale PVS were associated
with CAA defined according to clinical-radiologic cri-
teria.7 However, more studies are needed to defini-
tively determine the pathologic basis of MRI-visible
PVS.
We found no increased prevalence of basal gan-
glia PVS in CAA, consistent with deep perforating
arteries being largely spared by amyloid-b deposi-
tion.4 Previous studies report that neuroimaging
markers of hypertensive arteriopathy (lacunes, deep
cerebral microbleeds, and white matter changes) are
more strongly linked to basal ganglia than centrum
semiovale PVS, also suggesting that the distribution
of PVS may reflect the underlying arteriopathy.7,9–11
Since lobar ICHs are more likely to be surgically
evacuated, our sample of non-CAA ICH is biased
toward lobar ICH, which may contribute to the lack
of severe basal ganglia PVS in the non-CAA group.
However, non-CAA ICH cases more often had
milder (1–10) centrum semiovale PVS compared
to CAA cases.
Limitations of our study include the small cohort
and selection bias due to the requirement for T2-
weighted MRI. Because we included routinely col-
lected hematoma evacuation samples, which may be
suboptimal in comparison to postmortem examina-
tions, it was not possible to definitively assess whether
vessels were parenchymal or leptomeningeal in all pa-
tients. Due to limited tissue sampling, it is possible
that some non-CAA ICH patients might have had
undetected CAA. Moreover, the amount of available
tissue (and number of assessable cortical and leptome-
ningeal vessels) was generally higher in the CAA
group, which could have led to a greater chance of
sampling error in the non-CAA group. However, mis-
classification and small sample size would tend to bias
toward a null result. Although CAA patients were
older than non-CAA patients, the difference in severe
centrum semiovale PVS was robust to adjustment for
age; furthermore, the CAA group had a higher prev-
alence of PVS only in the centrum semiovale: con-
founding by age would be expected to increase PVS
severity in both the centrum semiovale and the basal
ganglia.7,10,23 Finally, although the PVS raters were
blinded to clinical and histopathologic information
as well as microbleeds status, it was impossible to
blind them to ICH presence.
Our findings are preliminary and hypothesis-
generating, requiring external validation in larger
independent cohorts with pathologic verification of
CAA. Nevertheless, if confirmed, PVS in the centrum
semiovale may help improve the sensitivity of MRI
for in vivo diagnosis of sporadic CAA in an appropri-
ate clinical context. Further studies are also needed to
determine whether centrum semiovale PVS precede
Figure MRI-visible white matter perivascular spaces in CAA and non-CAA ICH
Perivascular spaces (PVS) are defined as small sharply delineated structures of (or close to)
CSF intensity measuring ,3 mm and following the course of perforating or medullary ves-
sels in basal ganglia and centrum semiovale. In (A) and (B), the left panels show dot-like
hyperintensities (florid PVS) on representative axial T2-weighted MRI at 1.5T in the centrum
semiovale in patients with histopathologically confirmed cerebral amyloid angiopathy (CAA);
the right panels show the corresponding pathology (immunostaining for amyloid-b), with
dense amyloid deposition spanning the entire vessel wall of a cortical (A, right panel) and a
leptomeningeal arteriole (B, right panel). (C) and (D) show axial T2-weightedMRI from 2 of the
non-CAA cases, showing a paucity of centrum semiovale PVS. ICH 5 intracerebral
hemorrhage.
60 Neurology 82 January 7, 2014
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
other imaging features of CAA,26 which might help
identify CAA earlier in its natural history.
AUTHOR CONTRIBUTIONS
Statistical analysis was conducted by Dr. A. Charidimou and M. Burnell.
A. Charidimou: project design, data collection, data analysis, write-up.
Z. Jaunmuktane: data collection, histology review and classification, crit-
ical revisions. J-C. Baron: project design, data collection, critical revisions.
M. Burnell: data analysis, data interpretation, critical revisions. P. Varlet:
data collection, critical revisions. A. Peeters: data collection, critical revi-
sions. J. Xuereb: data collection, histology review and classification,
critical revisions. R. Jäger: imaging analysis advice, critical revisions.
S. Brandner: data collection, histology review and classification, critical
revisions. D. J. Werring: project design, data interpretation, supervision,
obtaining funding, write-up.
STUDY FUNDING
Part of this work was undertaken at UCLH/UCL, which received a pro-
portion of funding from the Department of Health’s NIHR Biomedical
Research Centres funding scheme.
DISCLOSURE
A. Charidimou receives research support from the Greek State Scholar-
ship Foundation, the Stroke Association, and the British Heart Founda-
tion. Z. Jaunmuktane, J.-C. Baron, M. Burnell, P. Varlet, A. Peeters,
J. Xuereb, R. Jäger, and S. Brandner report no disclosures. D. J. Werring
receives research support from the Department of Health/Higher Educa-
tion Funding Council for England (Clinical Senior Lectureship Award),
the Stroke Association, and the British Heart Foundation. Go to
Neurology.org for full disclosures.
Received April 26, 2013. Accepted in final form September 23, 2013.
REFERENCES
1. Pantoni L. Cerebral small vessel disease: from pathogenesis
and clinical characteristics to therapeutic challenges. Lan-
cet Neurol 2010;9:689–701.
2. Charidimou A, Gang Q, Werring DJ. Sporadic cerebral
amyloid angiopathy revisited: recent insights into patho-
physiology and clinical spectrum. J Neurol Neurosurg Psy-
chiatry 2012;83:124–137.
3. Viswanathan A, Greenberg SM. Cerebral amyloid angiop-
athy in the elderly. Ann Neurol 2011;70:871–880.
4. Vinters HV. Cerebral amyloid angiopathy. A critical
review. Stroke 1987;18:311–324.
5. Knudsen KA, Rosand J, Karluk D, Greenberg SM. Clin-
ical diagnosis of cerebral amyloid angiopathy: validation of
the Boston criteria. Neurology 2001;56:537–539.
6. van Rooden S, van der Grond J, van den Boom R, et al.
Descriptive analysis of the Boston criteria applied to a
Dutch-type cerebral amyloid angiopathy population.
Stroke 2009;40:3022–3027.
7. Charidimou A, Meegahage R, Fox Z, et al. Enlarged per-
ivascular spaces as a marker of underlying arteriopathy in
intracerebral haemorrhage: a multicentre MRI cohort
study. J Neurol Neurosurg Psychiatry 2013;84:624–629.
8. Cumurciuc R, Guichard JP, Reizine D, Gray F,
Bousser MG, Chabriat H. Dilation of Virchow-Robin
spaces in CADASIL. Eur J Neurol 2006;13:187–190.
9. Doubal FN, MacLullich AM, Ferguson KJ, Dennis MS,
Wardlaw JM. Enlarged perivascular spaces on MRI are a
feature of cerebral small vessel disease. Stroke 2010;41:
450–454.
10. Martinez-Ramirez S, Pontes-Neto OM, Dumas AP, et al.
Topography of dilated perivascular spaces in subjects from
a memory clinic cohort. Neurology 2013;80:1551–1556.
11. Rouhl RP, van Oostenbrugge RJ, Knottnerus IL, Staals JE,
Lodder J. Virchow-Robin spaces relate to cerebral small
vessel disease severity. J Neurol 2008;255:692–696.
12. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging
standards for research into small vessel disease and its con-
tribution to ageing and neurodegeneration. Lancet Neurol
2013;12:822–838.
13. Marin-Padilla M, Knopman DS. Developmental aspects of the
intracerebral microvasculature and perivascular spaces: insights
into brain response to late-life diseases. J Neuropathol Exp
Neurol 2011;70:1060–1069.
14. Weller RO, Djuanda E, Yow HY, Carare RO. Lymphatic
drainage of the brain and the pathophysiology of neuro-
logical disease. Acta Neuropathol 2009;117:1–14.
15. Arbel-Ornath M, Hudry E, Eikermann-Haerter K, et al.
Interstitial fluid drainage is impaired in ischemic stroke
and Alzheimer’s disease mouse models. Acta Neuropathol
2013;126:353–364.
16. Roher AE, Kuo YM, Esh C, et al. Cortical and leptome-
ningeal cerebrovascular amyloid and white matter pathol-
ogy in Alzheimer’s disease. Mol Med 2003;9:112–122.
17. Preston SD, Steart PV, Wilkinson A, Nicoll JA,
Weller RO. Capillary and arterial cerebral amyloid angi-
opathy in Alzheimer’s disease: defining the perivascular
route for the elimination of amyloid beta from the human
brain. Neuropathol Appl Neurobiol 2003;29:106–117.
18. Attems J, Jellinger K, Thal DR, Van Nostrand W. Review:
sporadic cerebral amyloid angiopathy. Neuropathol Appl
Neurobiol 2011;37:75–93.
19. Weller RO, Massey A, Newman TA, Hutchings M,
Kuo YM, Roher AE. Cerebral amyloid angiopathy: amyloid
beta accumulates in putative interstitial fluid drainage path-
ways in Alzheimer’s disease. Am J Pathol 1998;153:725–733.
20. Vonsattel JP, Myers RH, Hedley-Whyte ET, Ropper AH,
Bird ED, Richardson EP Jr. Cerebral amyloid angiopathy
Table 2 Diagnosis of cerebral amyloid angiopathy (CAA) using the original
Boston criteria (including strictly lobar microbleeds) with and without
the inclusion of severe centrum semiovale PVS (>20 PVS)a
Original Boston criteria
With inclusion of severe
centrum semiovale PVS
Pathologic diagnosis Pathologic diagnosis
Clinical diagnosis n CAA (1) CAA (2) n CAA (1) CAA (2)
Probable CAA 11 10 1 13 12 1
Nonprobable CAA 10 3 7 8 1 7
Possible CAA 4 2 2 3 1 2
Non-CAA 6 1 5 5 0 5
Total 21 13 8 21 13 8
Abbreviations: GRE5 gradient-recalled echo; PVS 5 perivascular spaces.
Only cases with T2*-GRE MRI were included in this analysis (n 5 21). Inclusion of severe
centrum semiovale PVS resulted in the diagnostic upgrading of 3 patients: 2 from possible
to probable CAA and 1 from non-CAA to possible CAA.
a To test whether the addition of severe centrum semiovale PVS as a criterion improves the
sensitivity and specificity of the classic Boston diagnostic criteria for CAA, we regarded
severe centrum semiovale PVS as another neuroimaging manifestation of CAA. Patients
were classified as CAA according to the original Boston criteria and with the addition of
severe centrum semiovale PVS. Lobar cerebral microbleeds were regarded as hemorrhagic
lesions in the criteria. The histopathologic information was not taken into account for the
classification.
Neurology 82 January 7, 2014 61
ª"NFSJDBO"DBEFNZPG/FVSPMPHZ6OBVUIPSJ[FESFQSPEVDUJPOPGUIJTBSUJDMFJTQSPIJCJUFE
without and with cerebral hemorrhages: a comparative his-
tological study. Ann Neurol 1991;30:637–649.
21. Greenberg SM, Vonsattel JP. Diagnosis of cerebral amy-
loid angiopathy. Sensitivity and specificity of cortical
biopsy. Stroke 1997;28:1418–1422.
22. Maclullich AM, Wardlaw JM, Ferguson KJ, Starr JM,
Seckl JR, Deary IJ. Enlarged perivascular spaces are
associated with cognitive function in healthy elderly
men. J Neurol Neurosurg Psychiatry 2004;75:1519–
1523.
23. Zhu YC, Tzourio C, Soumare A, Mazoyer B, Dufouil C,
Chabriat H. Severity of dilated Virchow-Robin spaces is
associated with age, blood pressure, and MRI markers of
small vessel disease: a population-based study. Stroke
2010;41:2483–2490.
24. Bossuyt PM, Reitsma JB, Bruns DE, et al. The STARD
statement for reporting studies of diagnostic accuracy:
explanation and elaboration. Ann Intern Med 2003;138:
W1–W12.
25. Weller RO, Subash M, Preston SD, Mazanti I, Carare RO.
Perivascular drainage of amyloid-beta peptides from the
brain and its failure in cerebral amyloid angiopathy and
Alzheimer’s disease. Brain Pathol 2008;18:253–266.
26. Deramecourt V, Slade JY, Oakley AE, et al. Staging and
natural history of cerebrovascular pathology in dementia.
Neurology 2012;78:1043–1050.
This Week’s Neurology® Podcast
Effect of head impacts on diffusivity measures in a cohort of col-
legiate contact sport athletes (See p. 63)
This podcast begins and closes with Dr. Robert Gross, Editor-in-
Chief, briefly discussing highlighted articles from the January 7,
2014, issue of Neurology. In the second segment, Dr. Noah Kolb
talks with Dr. Thomas McAllister about his paper on the effect of
head impacts on diffusivity measures in collegiate contact sport ath-
letes. Dr. Adam Numis reads our e-Pearl of the week about recurrent
rhabdomyolysis. In the next part of the podcast, Dr. Matt Barrett
focuses his interview with Dr. Dan Weintraub on management of
neuropsychiatric manifestations of Parkinson disease. Disclosures can be found at www.neurology.org.
At www.neurology.org, click on “RSS” in the Neurology Podcast box to listen to the most recent
podcast and subscribe to the RSS feed.
CME Opportunity: Listen to this week’s Neurology Podcast and earn 0.5 AMA PRA Category
1 CME Credits™ by answering the multiple-choice questions in the online Podcast quiz.
Commenting Online is Easier Now with WriteClick™
Have a comment on a recent Neurology® article you would like to share? Now it is easier and more
convenient. Neurology.org has launched WriteClick on the home page and sidebars of each article to
encourage remarks and debate among users.
WriteClick is restricted to comments about studies published in Neurology within the last eight
weeks.
Learn more at http://www.neurology.org/letters
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